Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C
Cancer. 1981 Oct 1;48(7):1569-81. doi: 10.1002/1097-0142(19811001)48:7<1569::aid-cncr2820480717>3.0.co;2-x.
Twenty year's (1959-1979) experience in the treatment of osteosarcoma at the Bone Tumor Center of the Istituto Ortopedico Rizzoli is presented. During this period 433 cases were recorded, but only 266 were considered. All the patients underwent surgery but after 1970 whole-lung irradiation (1971), immunotherapy (1971), and chemotherapy (1972 onward) were added as adjuvant therapies on a nonrandomized basis. In the group treated with surgery alone the prognosis was very poor: 10% survived nine years or more after the diagnosis, an average disease-free interval of 7.7 months and an average survival time of 13 months. Monolateral whole-lung irradiation had negative results and was abandoned after six cases. Adjuvant immunotherapy with irradiated autologous tumor cells gave moderately positive results in 16 patients, but only by delaying the appearance of first metastases, therefore increasing the time of survival. Adjuvant chemotherapy was performed with three different protocols: one protocol with ADM only and two protocols using VCR + MTX (at medium dose) + ADM, administered according to two different schedules. Superimposable results were obtained with these three regimens. With equal follow-up, the percentage of continuously disease-free patients treated with adjuvant chemotherapy was significantly higher than that of patients treated with surgery alone (P less than 0.001). The patients in the chemotherapy group who had relapses showed a prolonged time (mean = 12.3 months) to the onset of the first metastasis. Adjuvant chemotherapy caused virtually no morbidity and no deaths. Reference is made to the advantages of a large and homogeneous caseload deriving from a single institution to avoid preselection bias and evaluate the effectiveness of new therapeutic approaches when patient randomization has not been employed.
本文介绍了里佐利骨科研究所骨肿瘤中心二十年(1959 - 1979年)来治疗骨肉瘤的经验。在此期间共记录了433例病例,但仅对其中266例进行了分析。所有患者均接受了手术治疗,1970年后,在非随机的基础上增加了全肺照射(1971年)、免疫治疗(1971年)和化疗(1972年起)作为辅助治疗。单纯手术治疗组的预后非常差:10%的患者在诊断后存活九年或更长时间,平均无病生存期为7.7个月,平均生存时间为13个月。单侧全肺照射效果不佳,在治疗6例后被放弃。用经照射的自体肿瘤细胞进行辅助免疫治疗,16例患者取得了中度阳性结果,但仅通过延迟首次转移的出现,从而延长了生存时间。辅助化疗采用三种不同方案:一种仅含阿霉素的方案,两种使用长春新碱+甲氨蝶呤(中等剂量)+阿霉素的方案,并按照两种不同的给药时间表进行给药。这三种方案取得了相似的结果。在相同的随访期内,接受辅助化疗的持续无病患者百分比显著高于单纯手术治疗的患者(P < 0.001)。化疗组中复发的患者出现首次转移的时间延长(平均 = 12.3个月)。辅助化疗几乎未引起任何并发症和死亡。文中提到了来自单一机构的大量且同质病例的优势,即在未采用患者随机分组的情况下,可避免预选择偏倚并评估新治疗方法的有效性。